Studies and Research Projects

Below you find an overview of our ongoing projects. We are continuously updating this list to inform you about the actual project status.

Please don´t hesitate to contact us in case of any further questions.

Ongoing projects

  • Biomarker
  • Therapeutic studies
  • Drug development

ABCB1 genotyping

The brain is by far the most complex organ of the body. Brain cells are not capable of regeneration and therefore have to be particularly well protected from dangerous substances. One protection mechanism is a molecule that hinders the entrance of dangerous substances from blood capillaries into the brain.

 

The gene product of the ABCB1 gene, the P-glycoprotein, is a custodian molecule located at the blood-brain barrier. There, it impedes the intrusion of various substances into the brain– including many antidepressants. DNA sequence variants in the ABCB1 gene can thus predict the individual treatment response to such antidepressants. These sequence variants can be detected through an ABCB1 gene test (developed by the Max Planck Society, MPG). The results of this test deliver a decision aid for the physician with respect to the type and dosing of antidepressant medication.

Project Phase: product available

 

 

CRH gene chip

 

Researchers at the Max Planck Institute of Psychiatry (MPIP) have developed a gene chip for patients suffering from depression. This chip indicates the extent to which an increased corticotropin-releasing hormone (CRH) production can lead to the genesis of depression. More information can be found in the CRHR1 antagonist project description.

Project Status: proof of concept

CRH gene chip

Researchers at the Max Planck Institute of Psychiatry (MPIP) have developed a gene chip for patients suffering from depression. This chip indicates the extent to which an increased corticotropin-releasing hormone (CRH) production can lead to the genesis of depression. More information can be found in the CRHR1 antagonist project description.

Project Status: proof of concept

CRHR1 antagonist

It has been shown that many patients suffering from depression or anxiety disorders have an increased release of the corticotropin-releasing hormone (CRH). Various studies state a causal relationship between CRH overactivity and increased depressive symptoms (e.g., increased anxiety, sleep disorders, loss of appetite). These can be reduced via blockade of the receptor for CRH, the CRHR1 receptor. Therefore, patients with depressive symptoms that are caused by CRH benefit particularly well from a therapy with a CRH antagonist.  

Project Status: proof of concept

 

 

Neuropeptid S

In animal models, Neuropeptide S (NPS) has been shown to have an anxiolytic effect. Researchers at the Max Planck Institute of Psychiatry (MPIP) revealed that NPS could also be administered via nasal application. An analog of NPS, applicable via nasal spray, has the potential of becoming an innovative alternative to classical anxiety treatment.

Project Status: pre-clinical